| 摘要 |
A wound treatment administers a vasodilator by: (a) active transdermal treatment such as: by direct perfusion of the wound with the vasodilator, by an intradermal injection of the vasodilator about the wound and its surrounding skin area, by iontophoresis about the wound and its surrounding skin area with the vasodilator, by microdialysis of the wound with the vasodilator using one or more probe situated about the wound and its surrounding skin area; and/or by (b) passive transdermal treatment such as: by transcutaneous electrical stimulation (TENS) about the wound and its surrounding skin area while administering the vasodilator, or by a combination of the foregoing. The vasodilator can be calcitonin gene-related peptide (CGRP) with or without vasoactive intestinal polypeptide (VIP), nitric oxide (NO), nerve growth factor (NGF), or a combinations of the forgoing. Blood flow proximal the wound can be monitored during the treatment to derive a chemical/dose relationship of the vasodilator being administered in the treatment. |
